Valvular heart disease associated with fenfluramine-phentermine
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Fenfluramine and phentermine have been individually approved as anorectic agents by the Food and Drug Administration (FDA). When used in combination the drugs may be just as effective as either drug alone, with the added advantages of the need for lower doses of each agent and perhaps fewer side effects. Although the combination has not been approved by the FDA, in 1996 the total number of prescriptions in the United States for fenfluramine and phentermine exceeded 18 million. METHODS: We identified valvular heart disease in 24 women treated with fenfluramine-phentermine who had no history of cardiac disease. The women presented with cardiovascular symptoms or a heart murmur. As increasing numbers of these patients with similar clinical features were identified, there appeared to be an association between these features and fenfluramine-phentermine therapy. RESULTS: Twenty-four women (mean [+/-SD] age, 44+/-8 years) were evaluated 12.3+/-7.1 months after the initiation of fenfluramine-phentermine therapy. Echocardiography demonstrated unusual valvular morphology and regurgitation in all patients. Both right-sided and left-sided heart valves were involved. Eight women also had newly documented pulmonary hypertension. To date, cardiac surgical intervention has been required in five patients. The heart valves had a glistening white appearance. Histopathological findings included plaque-like encasement of the leaflets and chordal structures with intact valve architecture. The histopathological features were identical to those seen in carcinoid or ergotamine-induced valve disease. CONCLUSIONS: These cases arouse concern that fenfluramine-phentermine therapy may be associated with valvular heart disease. Candidates for fenfluramine-phentermine therapy should be informed about serious potential adverse effects, including pulmonary hypertension and valvular heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Early weight loss medications, such as fenfluramine (Fen-Phen) and sibutramine, were withdrawn due to severe cardiovascular and psychiatric side effects [3,4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“Certainly, starvation, very-low-calorie diets, liquid protein diets, and obesity surgeries have been associated with prolongation of the QTc interval and increased risk of malignant dysrhythmias (1), and various pharmacologic agents have either limited efficacy or considerable toxicity (70 -72).”
From Obesity and Cardiovascular Disease (2009) · cites this paper as [70]
Citations
Cites
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.
Pellikka, P. A., Tajik, A. J., Khandheria, B. K., Seward, J. B., Callahan, J. A., Pitot, H. C., & Kvols, L. K. (1993) · Circulation · doi:10.1161/01.cir.87.4.1188 · Cited by 614
Robiolio, P. A., Rigolin, V. H., Wilson, J. S., Harrison, J. K., Sanders, L. L., Bashore, T. M., & Feldman, J. M. (1995) · Circulation · doi:10.1161/01.cir.92.4.790 · Cited by 406
Doppler Echocardiography: Theory, Instrumentation, Technique, and Application
NISHIMURA, R. A., MILLER, F. A., CALLAHAN, M. J., BENASSI, R. C., SEWARD, J. B., & TAJIK, A. J. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60540-0 · Cited by 263
Primary pulmonary hypertension and fenfluramine use.
Brenot, F., Herve, P., Petitpretz, P., Parent, F., Duroux, P., & Simonneau, G. (1993) · Heart · doi:10.1136/hrt.70.6.537 · Cited by 251
Weir, E. K., Reeve, H. L., Huang, J. M. C., Michelakis, E., Nelson, D. P., Hampl, V., & Archer, S. L. (1996) · Circulation · doi:10.1161/01.cir.94.9.2216 · Cited by 218
Klein, A. L., Burstow, D. J., Tajik, A. J., Zachariah, P. K., Taliercio, C. P., Taylor, C. L., Bailey, K. R., & Seward, J. B. (1990) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(14)80299-x · Cited by 213
Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations
Redfield, M. M., Nicholson, W. J., Edwards, W. D., & Tajik, A. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-50 · Cited by 156
Self-citationHormonal responses to fenfluramine in depressed and control subjects
Mitchell, P. B., & Smythe, G. A. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90008-v · Cited by 99
Irreversible pulmonary hypertension after treatment with fenfluramine.
McMurray, J. J. V., Bloomfield, P. M., & Miller, H. (1986) · BMJ · doi:10.1136/bmj.292.6515.239-a · Cited by 50
Research works printed but not linked: 4
- Heuer L, 1978, Chir Prax, 23, 497
- Tajik AJ, 1978, Mayo Clin Proc, 53, 271
- Thorson AH, 1958, Acta Med Scand Suppl, 334, 99
- Morita T, 1983, Am Rev Respir Dis, 127, 747
Cited by
Items 201–300 of 1,001
Dravet Syndrome: A Review of Current Management
Wheless, J. W., Fulton, S. P., & Mudigoudar, B. D. (2020) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2020.01.005 · Cited by 126
Beneficial Effect of Diazoxide in Obese Hyperinsulinemic Adults1
Alemzadeh, R., Langley, G., Upchurch, L., Smith, P., & Slonim, A. E. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4852 · Cited by 112
Activation of Serotonin 2C Receptors in Dopamine Neurons Inhibits Binge-like Eating in Mice
Xu, P., He, Y., Cao, X., Valencia-Torres, L., Yan, X., Saito, K., Wang, C., Yang, Y., Hinton, A. O., Jr., Zhu, L., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.06.005 · Cited by 123
Effect of Orlistat in Obese Patients with Binge Eating Disorder
Golay, A., Laurent‐Jaccard, A., Habicht, F., Gachoud, J., Chabloz, M., Kammer, A., & Schutz, Y. (2005) · Obesity Research · doi:10.1038/oby.2005.208 · Cited by 119
Safety and tolerability of new-generation anti-obesity medications: a narrative review
Patel, D. K., & Stanford, F. C. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1435129 · Cited by 116
Pergolide use in Parkinson disease is associated with cardiac valve regurgitation
Baseman, D., O’Suilleabhain, P. E., Reimold, S. C., Laskar, S. R., Baseman, J. G., & Dewey, R. B. (2004) · Neurology · doi:10.1212/01.wnl.0000129842.49926.07 · Cited by 119
Primary Pulmonary Hypertension
Galiè, N., Manes, A., Uguccioni, L., Serafini, F., Rosa, M. D., Branzi, A., & Magnani, B. (1998) · CHEST Journal · doi:10.1378/chest.114.3_supplement.184s · Cited by 129
Reform of Drug Regulation — Beyond an Independent Drug-Safety Board
Ray, W. A., & Stein, C. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmsb053432 · Cited by 125
Rise and fall of anti-obesity drugs
Li, M.-F. (2011) · World Journal of Diabetes · doi:10.4239/wjd.v2.i2.19 · Cited by 117
Welch, J. T., & Lim, D. S. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.08.012 · Cited by 130
Gurley, B. J., Wang, P., & Gardner, S. F. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js9801844 · Cited by 115
Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies
Strzelczyk, A., & Schubert‐Bast, S. (2021) · CNS Drugs · doi:10.1007/s40263-020-00784-8 · Cited by 121
Treatment of obesity: an update on anti‐obesity medications
Halpern, A., & Mancini, M. C. (2003) · Obesity Reviews · doi:10.1046/j.1467-789x.2003.00083.x · Cited by 115
Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension
Egermayer, P., Town, G. I., & Peacock, A. (1999) · Thorax · doi:10.1136/thx.54.2.161 · Cited by 124
Wadden, T. A., Berkowitz, R. I., Womble, L. G., Sarwer, D. B., Arnold, M. E., & Steinberg, C. M. (2000) · Obesity Research · doi:10.1038/oby.2000.53 · Cited by 117
“This was the promise of the fenfluramine-phentermine combination until the fenfluramines were removed from the market in 1997 because of their association with valvular heart disease (”
BackgroundHeart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide
Camp, G. V., Flamez, A., Cosyns, B., Goldstein, J. W., Perdaens, C., & Schoors, D. (2003) · Neurology · doi:10.1212/01.wnl.0000083985.00343.f2 · Cited by 115
Murr, M. M., Balsiger, B. M., Kennedy, F. P., Mai, J. L., & Sarr, M. G. (1999) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(99)80082-1 · Cited by 115
Making Medicines Safer — The Need for an Independent Drug Safety Board
Wood, A. J. J., Stein, C., & Woosley, R. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812173392512 · Cited by 119
Five‐year extended follow‐up status of 10 patients with Dravet syndrome treated with fenfluramine
Ceulemans, B., Schoonjans, A., Marchau, F., Paelinck, B. P., & Lagae, L. (2016) · Epilepsia · doi:10.1111/epi.13407 · Cited by 114
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2017) · Epilepsia · doi:10.1111/epi.13634 · Cited by 110
Dopamine agonists and cardiac valvulopathy in Parkinson disease: A case–control study
Yamamoto, M., Uesugi, T., & Nakayama, T. (2006) · Neurology · doi:10.1212/01.wnl.0000238508.68593.1d · Cited by 113
Baumann, M. H., Ayestas, M. A., Dersch, C. M., Brockington, A., Rice, K. C., & Rothman, R. B. (2000) · Synapse · doi:10.1002/(sici)1098-2396(200005)36:2<102::aid-syn3>3.0.co;2-# · Cited by 111
Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype–targeted drugs
Meltzer, H. Y., & Roth, B. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70678 · Cited by 109
Nitric Oxide Deficiency in Fenfluramine- and Dexfenfluramine-induced Pulmonary Hypertension
Archer, S. L., Djaballah, K., Humbert, M. J. C., Weir, Ε. K., Fartoukh, M. S., DALL'AVA-SANTUCCI, J., Mercier, J., Simonneau, G., & Dinh‐Xuan, A. T. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.4.9802113 · Cited by 112
“Recently, anorexigens have been associated with cardiac valvular insufficiency ( 28 ).”
BackgroundAnti-obesity drugs and neural circuits of feeding
Adan, R. A. H., Vanderschuren, L. J. M. J., & ELAFLEUR, S. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.01.008 · Cited by 122
Elangbam, C. S., Job, L. E., Zadrozny, L. M., Barton, J. C., Yoon, L., Gates, L. D., & Slocum, N. (2008) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2008.03.005 · Cited by 115
Medical treatment of obesity: The past, the present and the future
Bray, G. A. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.015 · Cited by 109
“In July 1997 the first cases of valvular heart disease in patients taking Fen/Phen were reported [20].”
BackgroundWeight management in obesity – past and present
Haslam, D. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12771 · Cited by 97
Non-proliferative and Proliferative Lesions of the Cardiovascular System of the Rat and Mouse
Berridge, B. R., Mowat, V., Nagai, H., Nyska, A., Okazaki, Y., Clements, P., Rinke, M., Snyder, P. W., Boyle, M. C., & Wells, M. Y. (2016) · Journal of Toxicologic Pathology · doi:10.1293/tox.29.3s-1 · Cited by 118
“…(so called “onlays”) composed of stromal cells in a dense matrix of collagen and glycosaminoglycans that distorted the architecture of the affected valve leading to dysfunction and secondary cardiac insufficiency (patients presented with murmurs and congestive heart failure) (Connolly et al. 1997).”
BackgroundDrugs and Medical Devices: Adverse Events and the Impact on Women’s Health
Carey, J., Nader, N., Chai, P. R., Carreiro, S., Griswold, M. K., & Boyle, K. L. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.12.009 · Cited by 109
The utility of animal models to evaluate novel anti‐obesity agents
Vickers, S. P., Jackson, H. C., & Cheetham, S. C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01245.x · Cited by 122
Fibrosis and carcinoid syndrome: from causation to future therapy
Druce, M. R., Rockall, A., & Grossman, A. B. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.51 · Cited by 109
Principles From Clinical Trials Relevant to Clinical Practice: Part I
Califf, R. M., & DeMets, D. L. (2002) · Circulation · doi:10.1161/01.cir.0000023260.78078.bb · Cited by 108
Mechanisms underlying current and future anti-obesity drugs
Adan, R. A. H. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.12.001 · Cited by 117
Pawar, R. S., & Grundel, E. (2017) · Drug Testing and Analysis · doi:10.1002/dta.1980 · Cited by 107
Burgess, E., Lewanczuk, R., Bolli, P., Chockalingam, A., Cutler, H., Taylor, G., & Hamet, P. (1999) · Europe PMC (PubMed Central) · Cited by 115
Primary Pulmonary Hypertension Associated With the Use of Fenfluramine Derivatives
Simonneau, G., Fartoukh, M. S., Sitbon, O., Humbert, M. J. C., Jagot, J.-L., & Hervé, P. (1998) · CHEST Journal · doi:10.1378/chest.114.3_supplement.195s · Cited by 108
Serotonin Mechanisms in Heart Valve Disease II
Xu, J., Jian, B., Chu, R., Lu, Z., Li, Q., Dunlop, J., Rosenzweig-Lipson, S. J., McGonigle, P., Levy, R. J., & Liang, B. T. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64497-5 · Cited by 118
Schoonjans, A., Paelinck, B. P., Marchau, F., Gunning, B., Gammaitoni, A., Galer, B. S., Lagae, L., & Ceulemans, B. (2017) · European Journal of Neurology · doi:10.1111/ene.13195 · Cited by 104
Pharmacology of Drugs Used as Stimulants
Docherty, J., & Alsufyani, H. (2021) · Journal of clinical pharmacology · doi:10.1002/jcph.1918 · Cited by 86
Further Cases of Valvular Heart Disease Associated with Fenfluramine–Phentermine
Graham, D. J., & Green, L. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370911 · Cited by 105
Bray, G. A. (2001) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1011808701117 · Cited by 122
Li, M., & Cheung, B. M. Y. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03453.x · Cited by 100
Pulmonary hypertension associated with benfluorex exposure
Savale, L., Chaumais, M., Cottin, V., Bergot, E., Frachon, I., Prévôt, G., Pison, C. M., Dromer, C., Poubeau, P., Lamblin, N., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00188611 · Cited by 114
Sachdev, M., Miller, W. C., Ryan, T., & Jollis, J. G. (2002) · American Heart Journal · doi:10.1067/mhj.2002.126733 · Cited by 103
McCann, U. D. (1997) · JAMA · doi:10.1001/jama.278.8.666 · Cited by 102
Food and Drug Administration's Obesity Drug Guidance Document: A Short History
Colman, E. (2012) · Circulation · doi:10.1161/circulationaha.111.028381 · Cited by 101
Neuroendocrine tumors and fibrosis: An unsolved mystery?
Laskaratos, F., Rombouts, K., Caplin, M. E., Toumpanakis, C., Thirlwell, C., & Mandair, D. (2017) · Cancer · doi:10.1002/cncr.31079 · Cited by 101
Potential functional and pathological side effects related to off-target pharmacological activity
Lynch, J. J., Vleet, T. R. V., Mittelstadt, S. W., & Blomme, E. A. G. (2017) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2017.02.020 · Cited by 102
Jollis, J. G., Landolfo, C. K., Kisslo, J., Constantine, G. D., Davis, K. D., & Ryan, T. (2000) · Circulation · doi:10.1161/01.cir.101.17.2071 · Cited by 102
Michos, E. D., Lopez‐Jimenez, F., & Gulati, M. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029282 · Cited by 90
Lee, J. K., Dam, J. V., Morton, J. M., Curet, M. J., & Banerjee, S. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.102 · Cited by 99
“5 ), and some pharmacological therapies are associated with potentially life-threatening complications such as cardiac valvular defects (”
BackgroundReview Article: Herbal Approach for Obesity Management
Chandrasekaran, C. V., Vijayalakshmi, M. A., Prakash, K., Bansal, V. S., Meenakshi, J., & Amit, A. (2012) · American Journal of Plant Sciences · doi:10.4236/ajps.2012.327119 · Cited by 124
Cabergoline-Related Severe Restrictive Mitral Regurgitation
Pinero, A., Marcos‐Alberca, P., & Fortes, J. (2005) · New England Journal of Medicine · doi:10.1056/nejm200511033531822 · Cited by 98
Pediatric Obesity: Etiology and Treatment
Crocker, M. K., & Yanovski, J. A. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2009.06.007 · Cited by 122
Hepatic Injury in 12 Patients Taking the Herbal Weight Loss Aids Chaso or Onshido
Adachi, M., Saito, H., Kobayashi, H., Horie, Y., Kato, S., Yoshioka, M., & Ishii, H. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-6-200309160-00012 · Cited by 98
“Fenfluramine was once prescribed for weight loss but was withdrawn from clinical use because of cardiac complications (2).”
BackgroundSEROTONIN 5-HT2C RECEPTOR AGONISTS: POTENTIAL FOR THE TREATMENT OF OBESITY
Miller, K. J. (2005) · Molecular Interventions · doi:10.1124/mi.5.5.8 · Cited by 95
Obesity and reproduction: an educational bulletin
(2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.08.005 · Cited by 102
INTENSIVE THERAPIES FOR PEDIATRIC OBESITY
Yanovski, J. A. (2001) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70356-4 · Cited by 102
Treating the Obese Patient: Suggestions for Primary Care Practice
Anderson, D. A. (1999) · Archives of Family Medicine · doi:10.1001/archfami.8.2.156 · Cited by 95
Benfluorex and Unexplained Valvular Heart Disease: A Case-Control Study
Frachon, I., ETIENNE, Y., Jobic, Y., Gal, G. L., Humbert, M. J. C., & Leroyer, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010128 · Cited by 104
The epidemic of obesity and changes in food intake: the Fluoride Hypothesis
Bray, G. A. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.04.033 · Cited by 114
Ariazi, J. L., Duffy, K. J., Adams, D. F., Fitch, D. M., Luo, L., Pappalardi, M. B., Biju, M. P., DiFilippo, E. H., Shaw, T., Wiggall, K., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242503 · Cited by 98
Mechanisms of Function and Disease of Natural and Replacement Heart Valves
Schoen, F. J. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130257 · Cited by 88
Rare diseases bullet 5: Primary pulmonary hypertension
Peacock, A. (1999) · Thorax · doi:10.1136/thx.54.12.1107 · Cited by 105
Developmental basis for filamin-A-associated myxomatous mitral valve disease
Sauls, K., de Vlaming, A., Harris, B. S., Williams, K., Wessels, A., Levine, R. A., Slaugenhaupt, S. A., Goodwin, R. L., Pavone, L. M., Mérot, J., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs238 · Cited by 90
“–30 This murine phenotype is similar to individuals suffering from carcinoid valve disease due to elevated peripheral serotonin levels as well as those having received the ergot derivative, FenPhen, which functions as a SERT inhibitor and a serotonin receptor agonist.(23,24,31,32) Additionally, recent data suggests th…”
BackgroundTemporal trends and drug exposures in pulmonary hypertension: An American experience
Walker, A. M., Langleben, D., Korelitz, J., Rich, S., Rubin, L. J., Strom, B. L., Gonin, R., Keast, S., Badesch, D. B., Barst, R. J., et al. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.02.020 · Cited by 88
Self-citationBernheim, A. M., Connolly, H. M., Hobday, T. J., Abel, M., & Pellikka, P. A. (2007) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2006.12.002 · Cited by 93
Self-citationRegulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
Heal, D. J., Gosden, J., & Smith, S. L. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03549.x · Cited by 86
Smith, B. M., Smith, J. M., Tsai, J. H., Schultz, J. A., Gilson, C. A., Estrada, S. A., Chen, R. R., Park, D. M., Prieto, E. B., Gallardo, C. S., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.12.080 · Cited by 91
A Serotonin and Melanocortin Circuit Mediates d-Fenfluramine Anorexia
Xu, Y., Jones, J. E., Lauzon, D. A., Anderson, J. G., Balthasar, N., Heisler, L. K., Zinn, A. R., Lowell, B. B., & Elmquist, J. K. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5412-09.2010 · Cited by 85
“However, the drug was withdrawn from clinical use due to its adverse cardiopulmonary events (Connolly et al., 1997).”
BackgroundManagement of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome
Srikanth, S., & DEEDWANIA, P. C. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0683-0 · Cited by 99
The FDA and Drug Safety: A Proposal for Sweeping Changes
Furberg, C. D., Levin, A. A., Gross, P. A., Shapiro, R. S., & Strom, B. L. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.18.1938 · Cited by 93
“... FDA’s performance, to implement the following 5 recommendations: (1) give the FDA more direct legal authority to pursue violations, (2) authorize the adoption of a conditional drug approval policy, at least for selected drugs, (3) provide additional financial resources to support the safety operations, (4) mandate…”
BackgroundHay, J. W., Yu, W., & Ashraf, T. (1999) · PharmacoEconomics · doi:10.2165/00019053-199915010-00004 · Cited by 86
“short-acting calcium channel blockers, prophylactic lidocaine and type Ic anti-arrhythmics.[93-100]”
BackgroundEarly events in valvulogenesis: A signaling perspective
Barnett, J. V., & Desgrosellier, J. S. (2003) · Birth Defects Research Part C: Embryo Today: Reviews · doi:10.1002/bdrc.10006 · Cited by 83
Pharmacotherapy for childhood obesity: present and future prospects
Sherafat‐Kazemzadeh, R., Yanovski, S. Z., & Yanovski, J. A. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.144 · Cited by 94
Therapeutic Potential of 5-HT2CReceptor Agonists for Addictive Disorders
Higgins, G. A., & Fletcher, P. J. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00025 · Cited by 83
Absence of Cardiac Valve Dysfunction in Obese Patients Treated with Sibutramine
Bach, D. S., Rissanen, A. M., Mendel, C. M., Shepherd, G., Weinstein, S. P., Kelly, F., Seaton, T. B., Putel, B., Pekkarinen, T. A., & Armstrong, W. F. (1999) · Obesity Research · doi:10.1002/j.1550-8528.1999.tb00419.x · Cited by 85
Epigenetic Regulation of Adipogenesis in Development of Metabolic Syndrome
Pant, R., Firmal, P., Shah, V. K., Alam, A., & Chattopadhyay, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.619888 · Cited by 91
Heshka, S., Greenway, F., Anderson, J. W., Atkinson, R. L., Hill, J. O., Phinney, S. D., Miller-Kovach, K., & Xavier Pi-Sunyer, F. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00494-0 · Cited by 83
A resurging boom in new drugs for epilepsy and brain disorders
Younus, I., & Reddy, D. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1386553 · Cited by 57
Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome
Schoonjans, A., Lagae, L. G., & Ceulemans, B. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285615607726 · Cited by 83
“Valvular heart disease in patients treated with the ‘Fen–Phen’ combination was first described by Connolly and colleagues [Connolly et al. 1997].”
BackgroundDo dorsal raphe 5-HT neurons encode “beneficialness”?
Luo, M., Li, Y., & Zhong, W. (2016) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2016.08.008 · Cited by 90
Application of cross-species PET imaging to assess neurotransmitter release in brain
Finnema, S. J., Scheinin, M., Shahid, M., Lehto, J., Borroni, E., Bang-Andersen, B., Sallinen, J., Wong, E., Farde, L., Halldin, C., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3938-6 · Cited by 78
5‐Hydroxytryptamine Medications for the Treatment of Obesity
Burke, L. K., & Heisler, L. K. (2015) · Journal of Neuroendocrinology · doi:10.1111/jne.12287 · Cited by 80
Anti-Inflammatory Nutrition as a Pharmacological Approach to Treat Obesity
Sears, B., & Ricordi, C. (2011) · Journal of Obesity · doi:10.1155/2011/431985 · Cited by 78
Drug-target network in myocardial infarction reveals multiple side effects of unrelated drugs
Azuaje, F. J., Zhang, L., Devaux, Y., & Wagner, D. R. (2011) · Scientific Reports · doi:10.1038/srep00052 · Cited by 86
Structural insights into ligand recognition and selectivity for classes A, B, and C GPCRs
Lee, S. M., Booe, J. M., & Pioszak, A. A. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.05.013 · Cited by 92
Present and Future: Pharmacologic Treatment of Obesity
Glandt, M., & Raz, I. (2011) · Journal of Obesity · doi:10.1155/2011/636181 · Cited by 95
Disatian, S., Ehrhart, E. J., Zimmerman, S., & Orton, E. C. (2008) · PubMed · Cited by 100
Prevalence and Determinants of Valvulopathy in Patients Treated With Dexfenfluramine
Shively, B. K., Roldan, C. A., Gill, E. A., Najarian, T., & Loar, S. B. (1999) · Circulation · doi:10.1161/01.cir.100.21.2161 · Cited by 81
Armbruster, B. N., & Roth, B. L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.r400030200 · Cited by 80
Thinness and weight loss: beneficial or detrimental to longevity?
GAESSER, G. A. (1999) · Medicine & Science in Sports & Exercise · doi:10.1097/00005768-199908000-00007 · Cited by 81
Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential
Higgins, G. A., Fletcher, P. J., & Shanahan, W. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107417 · Cited by 82
Strom, B. L. (2006) · Pharmacoepidemiology · doi:10.1002/9780470059876.ch1 · Cited by 79
Fenfluramine-like cardiovascular side-effects of benfluorex
Boutet, K., Frachon, I., Jobic, Y., Gut‐Gobert, C., Leroyer, C., Carlhant-Kowalski, D., Sitbon, O., Simonneau, G., & Humbert, M. J. C. (2009) · European Respiratory Journal · doi:10.1183/09031936.00086308 · Cited by 84
Serotonin Modulation of Macrophage Polarization: Inflammation and Beyond
Casas-Engel, M. D. L., & Corbí, A. L. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-07320-0_9 · Cited by 85
Kars, M., Pereira, A. M., Bax, J. J., & Romijn, J. A. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0611 · Cited by 83
“drugs (ergotamine, methysergide) or anorectic drugs (fenfluramine) (3,4,5,6,7, 8 ).”
BackgroundKennett, G. A., & Clifton, P. G. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.020 · Cited by 83
5-Hydroxytryptamine 2C (5-HT2C) Receptor Agonists as Potential Antiobesity Agents
Nilsson, B. M. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm058240i · Cited by 75
Metadata
- Authors
- Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-08-28
- Volume
- 337
- Issue
- 9
- Pages
- 581-588
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2134362869
- Cited by
- 1,632
- References
- 14
- Citations by year
- 2026: 23 · 2025: 23 · 2024: 26 · 2023: 43 · 2022: 32 · 2021: 40 · 2020: 35 · 2019: 39 · 2018: 42 · 2017: 55 · 2016: 54 · 2015: 58 · 2014: 51 · 2013: 55 · 2012: 59
- FWCI
- 72.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Issues in Pregnancy
- Keywords
- valvular heart disease, pulmonary hypertension, anorectic agents, women, adverse drug reactions
- MeSH terms
- Adult, Aortic Valve Insufficiency, Appetite Depressants, Drug Combinations, Female, Fenfluramine, Heart Valve Diseases, Humans, Hypertension, Pulmonary, Middle Aged, Mitral Valve, Mitral Valve Insufficiency, Phentermine, Tricuspid Valve Insufficiency, Ultrasonography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.